These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16434127)

  • 1. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
    Dunachie SJ; Walther M; Vuola JM; Webster DP; Keating SM; Berthoud T; Andrews L; Bejon P; Poulton I; Butcher G; Watkins K; Sinden RE; Leach A; Moris P; Tornieporth N; Schneider J; Dubovsky F; Tierney E; Williams J; Heppner DG; Gilbert SC; Cohen J; Hill AV
    Vaccine; 2006 Apr; 24(15):2850-9. PubMed ID: 16434127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
    Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV
    Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
    Dunachie S; Berthoud T; Hill AV; Fletcher HA
    Vaccine; 2015 Sep; 33(40):5321-31. PubMed ID: 26256523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
    Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
    PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
    Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
    Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
    Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
    PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.
    Ockenhouse CF; Regules J; Tosh D; Cowden J; Kathcart A; Cummings J; Paolino K; Moon J; Komisar J; Kamau E; Oliver T; Chhoeu A; Murphy J; Lyke K; Laurens M; Birkett A; Lee C; Weltzin R; Wille-Reece U; Sedegah M; Hendriks J; Versteege I; Pau MG; Sadoff J; Vanloubbeeck Y; Lievens M; Heerwegh D; Moris P; Guerra Mendoza Y; Jongert E; Cohen J; Voss G; Ballou WR; Vekemans J
    PLoS One; 2015; 10(7):e0131571. PubMed ID: 26148007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
    Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
    Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
    Porter DW; Thompson FM; Berthoud TK; Hutchings CL; Andrews L; Biswas S; Poulton I; Prieur E; Correa S; Rowland R; Lang T; Williams J; Gilbert SC; Sinden RE; Todryk S; Hill AV
    Vaccine; 2011 Oct; 29(43):7514-22. PubMed ID: 21501642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
    Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
    J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
    Afolabi MO; Tiono AB; Adetifa UJ; Yaro JB; Drammeh A; Nébié I; Bliss C; Hodgson SH; Anagnostou NA; Sanou GS; Jagne YJ; Ouedraogo O; Tamara C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Duncan CJ; Cortese R; Nicosia A; Roberts R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampman B; Bejon P; Imoukhuede EB; Ewer KJ; Hill AV; Bojang K; Sirima SB
    Mol Ther; 2016 Aug; 24(8):1470-7. PubMed ID: 27109630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
    Imoukhuede EB; Berthoud T; Milligan P; Bojang K; Ismaili J; Keating S; Nwakanma D; Keita S; Njie F; Sowe M; Todryk S; Laidlaw SM; Skinner MA; Lang T; Gilbert S; Greenwood BM; Hill AV
    Vaccine; 2006 Oct; 24(42-43):6526-33. PubMed ID: 16842888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium.
    Rodríguez D; González-Aseguinolaza G; Rodríguez JR; Vijayan A; Gherardi M; Rueda P; Casal JI; Esteban M
    PLoS One; 2012; 7(4):e34445. PubMed ID: 22529915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus.
    Oliveira-Ferreira J; Miyahira Y; Layton GT; Savage N; Esteban M; Rodriguez D; Rodriguez JR; Nussenzweig RS; Zavala F
    Vaccine; 2000 Mar; 18(17):1863-9. PubMed ID: 10699335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.